Early studies with TCRs specific for NY-ESO-1, MART-1 or p53 [133] and a CAR directed against CD19 [155] showed that mRNA-transfected T cells efficiently lyse antigen-expressing tumor cells. The gene discussed is CD19; the disease is neoplasm.